Nov 11, 2022
Ymmunobio Presented Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200
Dr. Katrin Rupalla traveled to Boston for the Annual Meeting of the Society for Immunotherapy of Cancer. She shared our findings on the anti-tumor activity in vivo of Ymmunobio’s monoclonal antibody YB-200 and the significant increase in B-cell response in the tumor microenvironment.
Co-authors of Ymmunobio’s poster presentation are Michel Janicot, PhD, Ymmunobio, Alexej Schmidt, PhD, University of Umea, Sweden, and Iris Helfrich, PhD, Professor at the University of Munich, Germany.
TITLE: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment.
POSTER NUMBER: 1384
PRESENTERS: Dr. Katrin Rupalla, CEO, Ymmunobio AG, and Dr. Bernhard B. Singer, University Essen/Duisburg, Germany
DATE/TIME: Friday, November 11, 2022. Posters will be on display in Hall C from 9 a.m. to 9 p.m. EST. The full text of this year’s SITC abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement at 8:00 a.m. EST on Tuesday, Nov. 7, 2022 and available from the SITC website.